Last Updated: July 10, 2026
Medtech companies need a marketing leader who understands regulatory milestones, clinical evidence requirements, and payer dynamics – not someone learning your space while burning runway. You can't wait until FDA clearance to build go-to-market strategy.
The Healthcare & MedTech Marketing Problem
FDA timelines create unpredictable launch windows
510(k) clearance can slip 6-18 months. De novo and PMA pathways add even more uncertainty. Without a marketing leader who knows how to stage launch activities around regulatory milestones, teams either over-invest too early or scramble post-approval when competitors already own the clinical narrative. The cost is lost first-mover advantage in a market where physician adoption is slow to reverse.
Clinical evidence rarely translates to commercial messaging
Your clinical team can run a successful trial. Turning those endpoints into a sales story physicians actually respond to is a different skill set. Most medtech startups lack the marketing leadership to bridge clinical outcomes to value-based purchasing language, leaving sales reps improvising in the field while competitors with cleaner messaging win the evaluation.
Reimbursement complexity drives churn before it drives revenue
If your device requires prior authorization or lacks strong CPT code coverage, customer acquisition cost is only half the problem – retention breaks down when providers can't get reimbursed and pull back on utilization. Marketing teams that don't understand payer dynamics build demand for a product that stalls at billing, which kills referral pipelines before the product gets traction.
How We Navigate Healthcare & MedTech Marketing
We build go-to-market strategies for medtech companies that work within regulatory constraints instead of fighting them.
Assessment starts with your regulatory timeline. We map FDA milestones, cleared indications, and off-label risk areas before touching messaging. This defines the real commercial window and tells us what we can say, to whom, and when. Most engagements surface 2-3 compliance gaps in the first two weeks – language the sales team is using that creates exposure, or cleared indications the commercial team is underselling.
Strategy development integrates clinical evidence into your commercial stack. We work with medical affairs and regulatory to identify which study endpoints map to payer value frameworks and which ones land with clinical buyers. The deliverable is an evidence-based messaging architecture – a modular claims library your reps, digital team, and medical science liaisons can all draw from.
Execution focuses on the channels that move the needle in medtech: KOL programs, congress presence, peer-reviewed content placement, and targeted HCP digital campaigns. We build a measurement framework tied to leading indicators – clinical evaluation requests, payer coverage decisions, and formulary inclusion progress. Our growth strategy work covers the full commercial funnel from clinical evidence to closed deal.
What makes this different from hiring a full-time CMO: you get an operator embedded 15-25 hours per week, without the 12-month recruiting timeline or the $350K base salary. The fractional model gives you senior medtech marketing leadership right now at a fraction of the cost.
What we deliver
- Regulatory-aligned go-to-market plan staged around FDA approval milestones
- Evidence-based messaging architecture translating clinical endpoints into commercial language
- Reimbursement-informed acquisition model built around payer coverage realities
Medtech companies that win markets don't wait for FDA clearance to build commercial momentum – they stage it. Pre-clearance KOL relationships, payer engagement, and messaging architecture built 12 months out are what separate a strong launch from a slow ramp.
Our Methodology
Our methodology runs on a 90-day sprint with three phases. The first 30 days are diagnostic: we audit your marketing infrastructure, review your regulatory clearance status and claimed indications, interview clinical and commercial stakeholders, and identify the 3-5 highest-impact opportunities. We also assess payer coverage status and reimbursement gaps suppressing conversion.
Days 30-60 focus on strategy and early execution. We build the go-to-market roadmap tied to regulatory milestones, establish the messaging architecture, and start executing quick wins – typically tightening rep-facing materials and launching 1-2 targeted HCP digital campaigns. Measurement frameworks go live in this phase so every subsequent decision is data-driven.
Days 60-90 are full execution and optimization. Systems are running, the team knows their roles, and we're iterating on real performance data. Monthly reporting gives leadership visibility into clinical pipeline metrics, payer engagement progress, and commercial momentum – tied to revenue indicators, not vanity metrics.
How We Work
In the first 30 days, we conduct a full commercial and marketing audit. We review your analytics, map the clinical buyer journey, assess payer coverage status, and interview sales and clinical stakeholders. We establish baseline metrics before changing anything.
Days 30-60 are strategy and early execution. We build the go-to-market roadmap, align messaging with regulatory clearance boundaries, and start executing the highest-confidence channel plays. Weekly check-ins keep commercial and regulatory teams aligned.
Days 60-90 are full execution. Campaigns are running, reps have updated materials, and we're optimizing based on real data. Monthly presentations give leadership a clear view of what's working and what's changing.
Most engagements run 3-6 months initially, 15-25 hours per week embedded with your team. We attend leadership meetings, manage external vendors, and make resource allocation decisions. The goal is a commercial engine that runs without us once the engagement ends.
- Regulatory-aligned commercial strategy
- Clinical evidence commercialization
- Payer and reimbursement strategy
If your healthcare & medtech company needs fractional cxo leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does a fractional CMO cost for a medtech company?
Engagements typically run $15K-$25K per month depending on scope and time commitment. That compares to $300K-$450K in fully-loaded cost for a full-time CMO hire – plus a 4-6 month recruiting lag. For companies between FDA clearance and Series B, the fractional model gives you senior operator-level expertise without the overhead of a permanent hire you may not be ready to sustain.
How long before we see results from a fractional CMO engagement?
The first 30 days surface diagnostic insights and usually produce 2-3 quick wins – tightened messaging, a cleaner measurement framework, or a channel reallocation that stops spend waste. Structural improvements show measurable impact by day 60-90. The compounding effects – KOL program momentum, payer engagement progress, clinical pipeline velocity – become clear at the 3-6 month mark.
How does a fractional CMO integrate with clinical and regulatory teams?
We work directly with medical affairs, regulatory, and clinical operations from day one. Your cleared indications define what you can say, and your clinical evidence defines what you should say. We operate as a bridge between commercial and clinical, making sure messaging is both compliant and compelling. Weekly syncs with key stakeholders keep everything aligned.
What makes Winston Francois different from a traditional healthcare marketing agency?
Agencies execute campaigns. We own the commercial strategy and operate as part of your leadership team. That means we're in the room when regulatory, clinical, and commercial decisions get made – not receiving a brief after the fact and building assets around it. Our work is tied to your actual regulatory timeline and payer coverage status, not a generic medtech playbook.
How do you measure ROI from a fractional CMO engagement in medtech?
We track leading indicators tied to revenue: clinical evaluation requests, payer coverage decisions, formulary inclusion progress, and rep win rates by message track. Vanity metrics are reported but not optimized toward. By the end of the 90-day sprint, you should be able to draw a direct line from marketing activities to pipeline movement – and our measurement framework makes that connection visible.
What type of medtech company is the right fit for this engagement?
Best fit is a company that has cleared or is within 6-12 months of FDA clearance, has a defined commercial target (a specific indication, care setting, or HCP specialty), and needs to build go-to-market before the launch window opens. We work with medical device, diagnostics, and digital health companies from seed through Series C. Companies with cleared products struggling to ramp clinical adoption are also strong candidates.
